1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Era of Hope Scholar Award supports individuals who are early in their careers with significant potential to effect meaningful change in breast cancer. As the Intent of the FY26 BCRP Era of Hope Scholar Award is to recognize creative and innovative individuals rather than projects, the award’s central features include the Principal Investigator’s (PI’s) demonstrated ability to go beyond conventional thinking in their field and the innovative and meaningful contributions that they can make toward ending breast cancer. The Era of Hope Scholar Award requires exceptionally talented scientists that are among “the best and the brightest” in their field(s), with demonstrated experience forming effective partnerships and collaborations and strong potential for future leadership in breast cancer research. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.Distinctive Features:· The PI must commit a minimum of 25% level of time and effort during the period of performance to conduct breast cancer research under this award.· The research team must include two or more breast cancer consumer advocates.
Funding Opportunity Number: HT942526BCRPEOHS. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $4.9M total program funding.
Get alerted about grants like this
Save a search for “Defense Health Agency Contracting Activity - DHACA” or related topics and get emailed when new opportunities appear.
Search similar grants →According to the current listing, eligibility includes: Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility. Confirm the full requirements in the official notice before applying.
The current listing shows $4.9M total program funding. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for DoW Breast Cancer, Era of Hope Scholar Award are due July 8, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Yes — DoW Breast Cancer, Era of Hope Scholar Award is offered by Defense Health Agency Contracting Activity - DHACA and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Clinical Research Extension Award supports research that extends the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical studies by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.Distinctive Features:· The research team must include two or more breast cancer consumer advocates.· This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal. Funding Opportunity Number: HT942526BCRPCREA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $15.4M total program funding.
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Development Award provides successful applicants the time and resources needed to bring investigators and breast cancer consumer advocates together to establish a consortium framework and conduct preliminary research in support of an application to a future, full BCRP Transformative Breast Cancer Consortium Award (pending availability of funds). All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.Distinctive Features:· This is a development award and is a separate award mechanism from the full FY26 BCRP Transformative Breast Cancer Consortium Award (HT942526BCRPTBCCA). For FY26, investigators may be named as Consortium Director on an application submitted to either (but not both) of these award mechanisms.· Breast cancer consumer advocates must be active participants in the development and execution of the FY26 BCRP TBCCDA. Funding Opportunity Number: HT942526BCRPTBCCDA. Assistance Listing: 12.420. Funding Instrument: CA. Category: ST. Award Amount: $140K total program funding.
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Levels 1 and 2.Distinctive Features:· This funding mechanism allows for applications submitted under Funding Level 1 or Funding Level 2. Funding Level 2 also includes a Population Science Studies option. With compelling justification, population science studies may request higher levels of funding and an additional year in the period of performance.· This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal. Funding Opportunity Number: HT942526BCRPBTA12. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $31.8M total program funding.
The Eli Lilly and Company Foundation's 2026 Open Call opened June 1 and closes July 3, across three focus areas: Global Health, K-12 STEM Education, and Economic Mobility. But two of the three only fund Marion County, Indiana. Here is how to read the geographic fine print, why the funder's commercial identity shapes what wins, and how to position a proposal that actually fits.
Read articleThe Lilly Foundation's 2026 Open Call accepts pre-applications June 1 through July 3. Its three priorities — Global Health, K-12 STEM Education, and Economic Mobility — look national, but the education and mobility tracks concentrate heavily in Marion County, Indiana, while the health track funds cardiometabolic work abroad. Here's how to read the geography before you spend a week on a pre-application you can't win.
Read articleDARPA's Defense Sciences Office and Biological Technologies Office pre-released four SBIR XL topics on June 3 with proposals open June 24 and due July 22. Read the four as a single coordinated bet on the deployed soldier — sensing, recovery, power, and pathogen defense — and the strategy for filing across the quartet becomes clear.
Read article